Robert Chess Sells 3,504 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

Twist Bioscience Co. (NASDAQ:TWST) Director Robert Chess sold 3,504 shares of the stock in a transaction dated Thursday, December 5th. The stock was sold at an average price of $51.85, for a total transaction of $181,682.40. Following the transaction, the director now owns 21,641 shares in the company, valued at approximately $1,122,085.85. The trade was a 13.94 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Robert Chess also recently made the following trade(s):

• On Monday, November 11th, Robert Chess sold 3,600 shares of Twist Bioscience stock. The stock was sold at an average price of $47.26, for a total transaction of $170,136.00.

Twist Bioscience Stock Down 1.6 %

TWST opened at $46.47 on Thursday. The firm’s 50 day moving average is $45.81 and its 200-day moving average is $46.59. Twist Bioscience Co. has a 52-week low of $27.41 and a 52-week high of $60.90. The firm has a market capitalization of $2.76 billion, a P/E ratio of -12.91 and a beta of 1.82.

Institutional Investors Weigh In On Twist Bioscience

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TWST. Principal Financial Group Inc. grew its stake in shares of Twist Bioscience by 210.2% during the second quarter. Principal Financial Group Inc. now owns 122,911 shares of the company’s stock valued at $6,057,000 after acquiring an additional 83,287 shares in the last quarter. Massachusetts Financial Services Co. MA grew its stake in Twist Bioscience by 215.9% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 29,314 shares of the company’s stock valued at $1,324,000 after purchasing an additional 20,035 shares in the last quarter. Barclays PLC increased its holdings in Twist Bioscience by 214.8% during the 3rd quarter. Barclays PLC now owns 153,039 shares of the company’s stock worth $6,913,000 after purchasing an additional 104,420 shares during the last quarter. FMR LLC raised its position in shares of Twist Bioscience by 6.0% in the 3rd quarter. FMR LLC now owns 218,561 shares of the company’s stock valued at $9,875,000 after purchasing an additional 12,327 shares in the last quarter. Finally, BNP Paribas Financial Markets boosted its stake in shares of Twist Bioscience by 128.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 38,032 shares of the company’s stock valued at $1,718,000 after buying an additional 21,357 shares during the last quarter.

Analyst Ratings Changes

TWST has been the subject of several research reports. Barclays lowered their price objective on shares of Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a research note on Tuesday, November 19th. TD Cowen restated a “buy” rating and issued a $58.00 price objective on shares of Twist Bioscience in a report on Tuesday, November 26th. Evercore ISI boosted their target price on Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Robert W. Baird raised their price target on shares of Twist Bioscience from $46.00 to $48.00 and gave the company an “outperform” rating in a report on Tuesday, November 19th. Finally, Scotiabank boosted their price objective on shares of Twist Bioscience from $50.00 to $54.00 and gave the stock a “sector outperform” rating in a research note on Tuesday, November 19th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, Twist Bioscience currently has an average rating of “Moderate Buy” and an average target price of $51.90.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.